BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Mare-Bredemeijer EL, Metselaar HJ. Optimization of the use of Calcineurin inhibitors in liver transplantation. Best Pract Res Clin Gastroenterol. 2012;26:85-95. [PMID: 22482528 DOI: 10.1016/j.bpg.2012.01.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Cholongitas Ε, Koukoufiki A, Pipili C, Antoniadis N, Fouzas I, Haidich AB, Goulis I. Is everolimus linked to metabolic syndrome in liver transplant recipients? Indian J Gastroenterol 2019;38:348-55. [PMID: 31515763 DOI: 10.1007/s12664-019-00971-6] [Reference Citation Analysis]
2 Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 2014;27:1039-1049. [PMID: 24943720 DOI: 10.1111/tri.12372] [Cited by in Crossref: 107] [Cited by in F6Publishing: 89] [Article Influence: 13.4] [Reference Citation Analysis]
3 Kim JM, Kwon CH, Joh JW, Sinn DH, Lee S, Choi GS, Lee SK. Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: A randomized prospective study. Liver Transpl. 2016;22:209-216. [PMID: 26360125 DOI: 10.1002/lt.24336] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Klintmalm GB, Nashan B. The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant. 2014;2014:845438. [PMID: 24719752 DOI: 10.1155/2014/845438] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
5 Undre N, Baccarani U, Britz R, Popescu I. Pharmacokinetic Profile of Prolonged-Release Tacrolimus When Administered via Nasogastric Tube in De Novo Liver Transplantation: A Sub-Study of the DIAMOND Trial. Ann Transplant 2019;24:268-72. [PMID: 31086126 DOI: 10.12659/AOT.909693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Li ZT, Huang HF, Zeng Z. Pathogenesis and management of FK506- and CsA-induced post-transplant diabetes mellitus: Similarities and differences. Shijie Huaren Xiaohua Zazhi 2014; 22(8): 1093-1100 [DOI: 10.11569/wcjd.v22.i8.1093] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Huang B, Liu J, Li J, Schroder PM, Chen M, Deng R, Deng S. Once-daily prolonged-release tacrolimus versus twice-daily tacrolimus in liver transplantation. J Am Pharm Assoc (2003) 2019; 59: 816-823. e2. [PMID: 31521585 DOI: 10.1016/j.japh.2019.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
9 Sun B, Gao J, Shi W, Guo Y, Fan J, Zhang J, Li X, Liu G. The interleukin-17 G-197A polymorphism is associated with cyclosporine metabolism and transplant rejection in liver transplant recipients. Pharmacogenomics 2019;20:447-56. [PMID: 30799725 DOI: 10.2217/pgs-2018-0198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Bzeizi KI, Smith R, Albenmousa A, Dama M, Aba-Alkhail F, Jalan R, Broering D. Long-Term Outcomes of Everolimus Therapy in De Novo Liver Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Transplant Proc. 2021;53:148-158. [PMID: 33390288 DOI: 10.1016/j.transproceed.2020.09.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liu FC, Lin HT, Lin JR, Yu HP. Impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipients. Ther Clin Risk Manag 2017;13:1043-51. [PMID: 28860788 DOI: 10.2147/TCRM.S142348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
12 Adam R, Karam V, Delvart V, Trunečka P, Samuel D, Bechstein WO, Němec P, Tisone G, Klempnauer J, Rossi M, Rummo OO, Dokmak S, Krawczyk M, Pratschke J, Kollmar O, Boudjema K, Colledan M, Ericzon BG, Mantion G, Baccarani U, Neuhaus P, Paul A, Bachellier P, Zamboni F, Hanvesakul R, Muiesan P; European Liver Intestine Transplant Association (ELITA). Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant 2015;15:1267-82. [PMID: 25703527 DOI: 10.1111/ajt.13171] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
13 Ferreira-Silva M, Faria-Silva C, Baptista PV, Fernandes E, Fernandes AR, Corvo ML. Drug delivery nanosystems targeted to hepatic ischemia and reperfusion injury. Drug Deliv Transl Res 2021;11:397-410. [PMID: 33660214 DOI: 10.1007/s13346-021-00915-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Cholongitas E, Antoniadis N, Goulis I, Theocharidou E, Ιmvrios G, Giouleme O, Filis D, Mouloudi E, Akriviadis E, Fouzas I. Trough Levels of Everolimus Are Associated With Recurrence Rates of Hepatocellular Carcinoma After Liver Transplantation. Transplantation Proceedings 2019;51:450-3. [DOI: 10.1016/j.transproceed.2019.01.069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
15 Cholongitas Ε, Goulis I, Theocharidou E, Antoniadis N, Fouzas I, Giakoustidis D, Imvrios G, Giouleme O, Papanikolaou V, Akriviadis E, Vasiliadis T. Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience. Hepatol Int 2014;8:137-45. [DOI: 10.1007/s12072-013-9492-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
16 Junge G, Dumortier T, Schwende H, Fung J. mTOR inhibition in liver transplantation: how to dose for effective/safe CNI reduction? Transplant Proc. 2013;45:1979-1980. [PMID: 23769088 DOI: 10.1016/j.transproceed.2013.02.102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
17 Cholongitas Ε, Goulis I, Theocharidou E, Antoniadis N, Fouzas I, Imvrios G, Giouleme O, Angelaki A, Vasiliadis T, Papanikolaou V, Akriviadis E. Everolimus with or without mycophenolate mofetil in a liver transplantation setting: a single-center experience. Ann Gastroenterol 2018;31:613-20. [PMID: 30174399 DOI: 10.20524/aog.2018.0278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Nakase H, Yoshino T, Matsuura M. Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use. Inflamm Bowel Dis 2014;20:2151-6. [PMID: 25029618 DOI: 10.1097/MIB.0000000000000130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
19 Weismüller TJ, Lerch C, Evangelidou E, Strassburg CP, Lehner F, Schrem H, Klempnauer J, Manns MP, Haller H, Schiffer M. A pocket guide to identify patients at risk for chronic kidney disease after liver transplantation. Transpl Int 2015;28:519-28. [DOI: 10.1111/tri.12522] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
20 Moctezuma-Velazquez C, Márquez-Guillén E, Torre A. Obesity in the Liver Transplant Setting. Nutrients 2019;11:E2552. [PMID: 31652761 DOI: 10.3390/nu11112552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]